Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
Executive Summary
Merck’s strong Phase II data testing Keytruda with chemotherapy in first-line lung cancer may put pressure on future IO/IO combinations when it comes to toxicity, efficacy and – importantly – cost.
You may also be interested in...
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.
Under Fire, Bristol Plans To Pick Up The IO Pieces
Facing analysts jittery about the prospects for Opdivo/Yervoy in first-line lung cancer, Bristol boasts breadth of Phase III lung program, including IO/chemo studies, and variety of tumor types targeted.
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain
Bristol's filing of Yervoy/Opdivo in first-line lung cancer is delayed as the company drops its plans for accelerated approval, but could be on a more solid regulatory footing if the pivotal trial is successful. Meanwhile, AstraZeneca is using adaptive trial design to update MYSTIC, which could result in broader approvals.